Our Fragile X World is pleased to work with several patient advocacy organizations, research institutions, agencies, and other stakeholders to help improve the lives of people affected by fragile X.
Our Research Partners
Rush University Medical Center is a not-for-profit, 664-bed academic medical center in Chicago, Illinois. Rush is the home of a fragile X clinic that provides comprehensive patient care and family counseling.
The CIDD, located at the University of North Carolina at Chapel Hill, is a comprehensive program for services, research, and training relevant to individuals with developmental disabilities and their families.
The TEACCH Autism Program, located at the University of North Carolina at Chapel Hill, provides clinical services, social play and recreation groups, individual counseling for higher-functioning clients, and supported employment. In addition, research activities include psychological, educational, and biomedical studies.
The Institute for Public Health harnesses the strengths of WUSTL to address the complex health issues and health disparities facing the St. Louis, Missouri, region and the world.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH)
NICHD seeks to assure that every individual is born healthy, is born wanted, and has the opportunity to fulfill his or her potential for a healthy and productive life.
The mission of the Centers for Disease Control's National Center on Birth Defects and Developmental Disabilities (NCBDDD) is to save babies by studying and addressing the causes of birth defects; help children reach their potential by understanding developmental disabilities; reduce complications of blood disorders; and improve the health of people living with disabilities.
The mission of NC TraCS is to accelerate clinical and translational research from health science to discovery to dissemination to patients and communities.
Novartis Pharmaceuticals is a former OFXW partner who works closely with over 800 patient advocacy organizations, multiple leading research institutions, and other key stakeholders around the world to enhance science-based innovation and deliver life-saving treatments to people who need them.